Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Mebeverine hydrochloride 135mg film-coated tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Mebeverine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Mebeverine hydrochloride

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for This medicine contains mebeverine hydrochloride which belongs to a group of medicines called antispasmodics. This medicine is used to treat symptoms of irritable bowel syndrome (IBS) and similar problems such as chronic irritable colon, spastic constipation, mucous colitis and spastic colitis. Irritable bowel syndrome (IBS) is a very common condition which causes spasm and pain in the gut or intestine. The intestine is a long muscular tube which food passes down so it can be digested. If the intestine goes into spasm and squeezes too tightly, you get pain. The way this medicine works is by relieving the spasm, pain and other symptoms of IBS. The main symptoms of irritable bowel syndrome (IBS) include:

  • stomach pain and spasm
  • feeling bloated and having wind
  • having diarrhoea (with or without constipation)
  • small, hard, pellet-like or ribbon-like stools (faeces) These symptoms may vary from person to person. Talk to your doctor or pharmacist if these symptoms do not improve after a while, if you develop new symptoms, or you are concerned about your symptoms. Your diet and lifestyle can also help treat IBS: How you restrict your diet depends on the way IBS affects you. If you find that certain foods bring on the symptoms, then it makes sense not to eat them. A high fibre diet may help, but ask your pharmacist for more information. Some people find that learning to relax can help to lessen their symptoms of IBS. You may find it helpful to set aside a few moments each day to relax and gently unwind.

What you need to know before you take it

e this medicine Do not take this medicine if:

  • you are allergic to mebeverine hydrochloride or any of the other ingredients of this medicine (listed in section 6). If the above applies to you, do not take this medicine and talk to your doctor or pharmacist.

Warnings and precautions Talk to your doctor or pharmacist before taking this medicine:

  • if you have developed new symptoms or your symptoms have become worse.
  • if you have liver or kidney problems. If the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine. Children and adolescents Mebeverine hydrochloride 135mg film-coated tablets are not recommended for use in children and adolescents below the age of 18, due to insufficient data on safety and efficacy. Other medicines and Mebeverine hydrochloride Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Mebeverine hydrochloride with food, drink and alcohol You can drink alcohol while you are taking this medicine. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy There is only limited information about the safety of mebeverine hydrochloride for pregnant women. Your doctor may advise you to stop taking this medicine before you become pregnant or as soon as you know you are pregnant. Breast-feeding This medicine should not be used during breast-feeding. Driving and using machines This medicine is not likely to affect your ability to drive or use any tools or machines. This medicine contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

How to take it

this medicine Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

  • The number of tablets you take can be lowered if your symptoms improve.
  • Do not take more than 3 tablets per day.
  • Try to take the tablet twenty minutes before a meal; some people find their symptoms are strongest after they have eaten.
  • Swallow the tablet whole with water. Do not chew the tablet. Adults (including the elderly)
  • Take 1 tablet 3 times a day.

If you take more of this medicine than you should If you or someone else takes too much of this medicine (an overdose), talk to a doctor or go to a hospital straight away. Take the medicine pack with you. If you forget to take this medicine If you miss a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose.

If you stop taking this medicine Do not stop taking this medicine without talking to your doctor, even if you feel better. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4 Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any of these serious side effects, stop taking this medicine. See a doctor at once:

  • Difficulty in breathing, swelling of face, neck, tongue or throat (severe allergic reactions). These other effects are less serious. If they bother you talk to a pharmacist:
  • Skin rash, red itchy skin. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The Yellow Card Scheme (website: www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting

Possible side effects

you can help provide more information on the safety of this medicine.

What this medicine looks like and contents of the pack Mebeverine hydrochloride 135mg film-coated tablets are white coloured, round shaped, biconvex film-coated tablets and plain on both sides. Packs may contain 10, 15, 84 or 100 film-coated tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Aspire Pharma Limited Unit 4, Rotherbrook Court Bedford Road Petersfield Hampshire GU32 3QG United Kingdom Alternative Manufacturer Wave Pharma Limited Ground Floor, Cavendish House 369, Burnt Oak Broadway Edgware HA8 5AW United Kingdom This leaflet was last revised in 01/2023.

How to store it

this medicine

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is

stated on the carton and blister pack after EXP. The expiry date refers to the last day of that month.

  • This medicine does not require any special storage conditions.
  • Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What this medicine contains The active substance is mebeverine hydrochloride. Each tablet contains 135mg of mebeverine hydrochloride. The other ingredients are: Core tablet Microcrystalline cellulose, lactose monohydrate, sodium starch glycolate type A, povidone, magnesium stearate, talc. Film coating Opadry white (ingredients: hypromellose (E464), titanium dioxide (E171), polyethylene glycol/macrogol and talc).

DRUGS/TS/23/2007

1010408-P3.1

Frequently asked questions about Mebeverine hydrochloride 135mg film-coated tablets

How do I take Mebeverine hydrochloride 135mg film-coated tablets?

Mebeverine hydrochloride 135mg film-coated tablets comes as tablet containing 135mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Mebeverine hydrochloride 135mg film-coated tablets?

The active substance in Mebeverine hydrochloride 135mg film-coated tablets is mebeverine hydrochloride.

Are there equivalent medicines to Mebeverine hydrochloride 135mg film-coated tablets?

Medicines with the same active substance, strength and form include: Boots IBS Symptom Relief 135mg Tablets, Mebeverine 135mg film-coated tablets, Mebeverine hydrochloride 135 mg Film-coated Tablets. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Mebeverine hydrochloride 135mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Mebeverine hydrochloride 135mg film-coated tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Mebeverine hydrochloride (7 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

For the symptomatic treatment of irritable bowel syndrome and other conditions usually included in this grouping, such as: chronic irritable colon, spastic constipation, mucous colitis, spastic colitis. The medicine is effectively used to treat the symptoms of these conditions, such as: colicky abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.

4.2. Posology and method of administration

For oral use.

The coated tablets should be swallowed with a sufficient amount of water (at least 100 ml water). They should not be chewed because of the unpleasant taste.

Duration of use is not limited.

If one or more doses are missed, the patient should continue with the next dose as prescribed; the missed dose(s) should not be taken in addition to the regular dose.

Adults (including the elderly):

One tablet three times a day, preferably 20 minutes before meals. After a period of several weeks, when the desired effect has been obtained, the dosage may be gradually reduced.

Paediatric Population

Mebeverine 135 mg film-coated tablets are not recommended for use in children and adolescents below 18, due to insufficient data on safety and efficacy.

Special Population

No posology studies in elderly, renal and/or hepatic impaired patients have been performed. No specific risk for elderly, renal and/or hepatic impaired patients could be identified from available post-marketing data. No dosage adjustment is deemed necessary in elderly, renal and/or hepatic impaired patients.

4.3. Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Since Mebeverine film-coated tablets contain lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5. Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed, except with alcohol. In vitro and in vivo studies in animals have demonstrated the absence of any interaction between mebeverine hydrochloride and ethanol.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no or limited amounts of data from the use of mebeverine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). Mebeverine is not recommended during pregnancy.

Breastfeeding

It is unknown whether mebeverine or its metabolites are excreted in human milk. The excretion of mebeverine in milk has not been studied in animals. Mebeverine should not be used during breast-feeding.

Fertility

There are no clinical data on male or female fertility; however, animal studies do not indicate harmful effects of mebeverine (see section 5.3).

4.7. Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. The pharmacodynamic and pharmacokinetic profile as well as postmarketing experience do not indicate any harmful effect of mebeverine on the ability to drive or to use machines.

4.8. Undesirable effects

The following adverse reactions have been reported spontaneously during postmarketing use. A precise frequency cannot be estimated from available data.

Allergic reactions mainly but not exclusively limited to the skin have been observed.

Immune system disorders:

Hypersensitivity (anaphylactic reactions)

Skin and subcutaneous tissue disorders:

Urticaria, angioedema, face oedema, exanthema.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Theoretically CNS excitability may occur in cases of overdose. In cases where mebeverine was taken in overdose, symptoms were either absent or mild and usually rapidly reversible. Observed symptoms of overdose were of a neurological and cardiovascular nature.

No specific antidote is known and symptomatic treatment is recommended.

Gastric lavage should only be considered in case of multiple intoxication or if discovered within about one hour. Absorption reducing measures are not necessary.

💬 Ask about this leaflet

Ask anything about Mebeverine hydrochloride 135mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →